source
- Solstice Oncology secures $225M Series A to advance CTLA-4 antibody porustobart in colon cancerSolstice Oncology, a biotech startup focused on immunotherapy, announced it has raised $225 million in a Series A financing round. The funding will support development of its lead candidate, a CTL…
- UK commission proposes new framework to regulate AI-driven medical toolsA UK commission released a report on Thursday outlining 44 recommendations for how artificial intelligence should be governed in the medical sector. The guidance aims to capture AI's promise, such…